Thomas Lamy

This profile gathers the share dealings of Thomas Lamy in Biosynex, where the filings describe the role as chief executive. In total, 14 filings cover trades dated from 19 April 2021 to 28 January 2025.

On the open market, the record shows 2 purchases worth €173k and 10 sales worth €3.3M. Sales outweigh purchases by €3.1M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 2 option exercises. So far in 2025, the count stands at no purchases and 1 sale.

The record was last updated on 3 February 2025 with an open-market sale (€1,682) in Biosynex. The last purchase on record was published on 14 February 2022, which is 1,706 days ago. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from AMF disclosures alone and does not predict where the share price will go.